Intermittent BRAF inhibition in advanced BRAF mutated melanoma: results of a phase II randomized trial
收藏官方服务：
资源简介：
Data sets from the phase II clinical study of A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (ClinicalTrials.gov Identifier: NCT02583516).
创建时间：
2021-01-01
